Glaucoma and Diabetes: Causes, Symptoms, and Prevention

Glaucoma in diabetes has two distinct presentations that deserve separate attention. Primary open-angle glaucoma — the most common form, age-related and chronic — occurs at modestly elevated rates in adults with diabetes (approximately 1.5 times the non-diabetic rate). Neovascular glaucoma is a more dangerous diabetes-specific complication, developing from advanced proliferative diabetic retinopathy when abnormal blood vessels grow on the iris and block the eye’s drainage angle. Both forms are largely asymptomatic in early stages — annual dilated eye exams are essential. The good news is that effective treatments exist for both forms, and early detection produces excellent outcomes. This guide covers the scope of the problem, distinguishing the two forms, and the diabetes-specific treatment considerations.

The Scope of the Problem

Primary Open-Angle Glaucoma

• Most common form (~70-90% of glaucoma cases).
• Slow, painless progression over years to decades.
• Drainage angle is open but fluid drainage is reduced.
• Eye pressure (IOP) rises gradually.
• Optic nerve damage and characteristic visual field loss develop.
• Vision loss starts peripherally; central vision preserved until late.
• Asymptomatic until significant damage has occurred — screening essential.
• Risk factors: age, family history, African or Hispanic descent, elevated IOP, diabetes, thin corneas.

Neovascular Glaucoma — The Diabetes-Specific Variant

• Develops from advanced proliferative diabetic retinopathy.
• Mechanism: ischemic retina releases VEGF (vascular endothelial growth factor) — same molecule targeted by macular edema treatments.
• VEGF drives abnormal blood vessel growth on the iris (rubeosis iridis) and in the drainage angle.
• New vessels block the trabecular meshwork drainage system.
• IOP rises rapidly — often to 40-50+ mmHg (normal 10-21).
• Symptoms: severe eye pain, redness, blurred vision, rapidly progressive vision loss.
• Emergency treatment required to prevent total vision loss.
• Once established, neovascular glaucoma has worse prognosis than open-angle glaucoma.

Symptoms — Why Screening Matters

Diagnosis

• Tonometry: measures intraocular pressure (IOP); normal range 10-21 mmHg.
• Dilated fundoscopy: visualizes optic nerve appearance; cup-to-disc ratio >0.5 suggests glaucoma.
• Visual field testing: detects characteristic peripheral vision loss patterns.
• OCT of optic nerve: measures nerve fiber layer thickness; sensitive for early changes.
• Gonioscopy: examines the drainage angle to distinguish open-angle vs angle-closure.
• Pachymetry: measures corneal thickness; affects IOP measurements.
• Annual comprehensive dilated eye exam is recommended for all adults with diabetes.

Treatment of Primary Open-Angle Glaucoma

The Beta-Blocker Drop Consideration

• Topical beta-blocker drops (timolol, betaxolol) can be absorbed systemically.
• Systemic effects: bradycardia, bronchospasm in asthmatics, and theoretical hypoglycemia awareness blunting.
• For adults with diabetes, this is generally a minor concern but worth knowing.
• Cardioselective topical beta-blockers (betaxolol) have less systemic effect.
• Punctal occlusion (pressing on tear duct) for 2-3 minutes after drops reduces systemic absorption.
• Prostaglandin analogs, alpha agonists, and CAI drops are usually preferred first-line in adults with diabetes.

Neovascular Glaucoma Treatment

• Anti-VEGF injections: aflibercept, ranibizumab, faricimab — reverses neovascularization.
• Pan-retinal laser photocoagulation: addresses underlying ischemic retina driving VEGF release.
• IOP-lowering medications: multiple drops often needed.
• Cyclophotocoagulation: laser to ciliary body reduces aqueous humor production.
• Glaucoma drainage implants: standard trabeculectomy often fails; tube shunts more successful.
• Optimized glucose control: addresses the underlying pathology driving the entire process.
• Despite treatment, vision prognosis is often guarded — early intervention matters.

Prevention Strategies

• Annual dilated eye exam: catches early changes before vision loss.
• Glucose control: reduces retinopathy progression and neovascular glaucoma risk.
• Treat retinopathy aggressively: anti-VEGF and laser treatment prevents neovascular glaucoma.
• Blood pressure control: hypertension worsens both retinopathy and glaucoma.
• Smoking cessation: smoking increases glaucoma risk.
• Family history awareness: 4× higher risk with first-degree relative; share with ophthalmologist.
• Adherence to glaucoma drops: if prescribed, daily use is essential.

Other Diabetic Eye Conditions

• Diabetic retinopathy — most common diabetic eye disease; leading cause of blindness in working-age adults.
• Diabetic macular edema — affects central vision.
• Cataracts — see our cataracts and diabetes guide.
• Dry eye — see our dry eye and diabetes guide.
• Cranial nerve palsies — can occur with sudden glucose changes; usually self-resolving.
• Annual comprehensive eye exam catches multiple conditions.

Drug Interactions to Watch

• Topical beta-blockers can be absorbed systemically; relevant in adults on systemic beta-blockers for hypertension.
• Steroid eye drops (sometimes used for inflammation) can raise IOP and blood glucose.
• Some glaucoma surgeries require post-operative steroids — coordinate diabetes management.
• Antihistamines (oral or topical) can worsen angle-closure in susceptible individuals.
• Topiramate and certain other medications can rarely cause angle-closure glaucoma.

Practical Daily Strategies

• Annual dilated eye exam for all adults with diabetes — earlier and more often if retinopathy present.
• If glaucoma drops prescribed, take them daily without skipping.
• Use punctal occlusion to reduce systemic absorption of glaucoma drops.
• Maintain A1C control to reduce retinopathy and neovascular glaucoma risk.
• Control blood pressure.
• Stop smoking.
• Address vision changes promptly — don’t wait for the annual exam if symptoms develop.
• Family history matters — share with ophthalmologist.

The Bottom Line

Glaucoma in diabetes has two distinct presentations. Primary open-angle glaucoma — the most common form, age-related and chronic — occurs at approximately 1.5 times the rate in adults with diabetes versus non-diabetic peers. The relationship is bidirectional and not as strong as for cataracts or retinopathy. Neovascular glaucoma is a more dangerous diabetes-specific complication, developing from advanced proliferative diabetic retinopathy when VEGF drives abnormal blood vessel growth on the iris and in the drainage angle — emergency treatment is required. Primary open-angle glaucoma is largely asymptomatic until late stages; annual dilated eye exams are essential for early detection. Treatment with eye drops (prostaglandin analogs preferred first-line in diabetes; topical beta-blockers can have systemic effects), laser (SLT), or surgery effectively lowers IOP and preserves vision when started early. Neovascular glaucoma requires anti-VEGF injections, pan-retinal laser, and pressure-lowering treatment urgently. Prevention strategies — glucose control, blood pressure management, smoking cessation, aggressive retinopathy treatment — substantially reduce both forms of glaucoma. African American and Hispanic adults have higher baseline rates and need particular attention. Family history of glaucoma (4× risk) should be shared with the ophthalmologist. For all adults with diabetes, annual dilated eye exams are non-negotiable — they catch glaucoma, retinopathy, cataracts, and macular edema before vision loss occurs. See our broader diabetic eye complications guides for context.